Nesta página
AGIO Agios Pharmaceuticals, Inc. - Common Stock
NASDAQ · Biotechnology · Ver em SEC EDGAR ↗ fechar Out 2, 2026 10-K/10-Q Jul 30, 2026
$31,80
· % da faixa de 52 semanas
· acima do mínimo
· para alta
$22,24mínima 52 sem
$46,00máxima 52 sem
Capitalização de Mercado (MRQ)
$1.90B
P/E (TTM)
-4.5
EPS (TTM)
$-7.02
Receita (TTM)
$98M
seus distintivos
Intervalo 52 Semanas
$22–$46
Classificação do Analista
BUY
Preço-Alvo
$46
P/E
-4.5
ROE
-34.3%
Margem de Lucro Líquido
-418.2%
Sua barra de distintivos está vazia — fixe uma métrica em qualquer lugar desta página.
AGIO Instantâneo da Ação Preço, capitalização de mercado, P/E, EPS, ROE, dívida/patrimônio, intervalo de 52 semanas
Preço
$31.80
Capitalização de Mercado (MRQ)
$1.90B
P/E (TTM)
-4.5
EPS (TTM)
$-7.02
Receita (TTM)
$98M
ROE (TTM)
-34.3%
Intervalo 52 Semanas
$22–$46
AGIO Gráfico de Preço da Ação OHLCV diário com indicadores técnicos — panorâmica, zoom e personalize sua visualização
intervalo
barras
A granularidade da barra se adapta ao período selecionado — passe o mouse sobre o gráfico para ver a abertura/máxima/mínima/fechamento de uma barra.
Sobre Agios Pharmaceuticals, Inc. - Common Stock Visão geral da empresa da Wikipedia
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 (or 2007) by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013.
History
In 2012, Agios was named among the defendants in a lawsuit against one of its founders, Craig Thompson, alleging that Thompson used research illegally taken from the Abramson Family Cancer Research Institute in research at Agios.
In May 2016, the company announced it would launch partnership with Celgene, developing metabolic immuno-oncology therapies and licensing AG-221 as well as AG-881 to Celgene, potentially garnering Agios $120 million in drug licensing payments.
In April 2017, the company raised $250 million in a new stock offering in anticipation of approval for its first cancer drug, enasidenib, by the US Food and Drug Administration.
In December 2017, the company filed a New Drug Application with the US FDA for ivosidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an IDH1 mutation.
In November 2019, Agios announced an underwritten public offering of 8,250,000 shares of common stock at a price of $31.00 per share which would result in approximately $256 million aggregate gross proceeds.
In April 2022, the FDA approved mitapivat as first disease-modifying therapy for hemolytic anemia in adults with pyruvate kinase deficiency.
Corporate governance
As of August 2022, Agios' CEO is Brian Goff.
Agios was established as a private company and converted to a public company with its initial public offering in July 2013 and subsequent listing on NASDAQ.
== References ==
Fonte: Wikipedia (Inglês), CC BY-SA 4.0 · Ver na Wikipedia ↗
setorHealthcare
indústriaBiotechnology
funcionários539
paísUS
Desempenho de 10 Anos Tendências de receita, lucro líquido, margens e EPS
Receita$54M2016-12-31 → 2025-12-31
EPS$-7.122019-12-31 → 2025-12-31
Fluxo de caixa livre$-377M2016-12-31 → 2025-12-31
Margem líquida-418.2%2017-12-31 → 2025-12-31
Avaliação e Proporções
Avaliação Rácios P/E, P/S, P/B, EV/EBITDA — a ação está cara ou barata?
| Métrica | Tendência de 5 anos | AGIO | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| P/E (TTM) | -4.5média 5A ≈-2.0 | ≈-2.0 | · | · | |
| P/S (TTM) | 19.3média 5A ≈59.0 | ≈59.0 | 25.9 | Valor justo | |
| P/B (MRQ) | 1.8média 5A ≈1.4 | ≈1.4 | 6.0 | Subvalorizado | |
| Preço / FCF (TTM) | -5.2média 5A ≈-4.5 | ≈-4.5 | · | · | |
| Preço / Fluxo de Caixa (TTM) | -5.3média 5A ≈-4.5 | ≈-4.5 | · | · | |
| Price / Tangible Book (Preço / Valor Patrimonial Tangível) | 2013.9média 5A ≈1.4 | ≈1.4 | · | · |
A mediana dos pares é calculada em uma base padronizada por métrica e pode não corresponder sempre à base TTM/MRQ mostrada para esta ação.
Lucratividade Margens bruta, operacional e líquida; ROE, ROA, ROIC
| Métrica | Tendência de 5 anos | AGIO | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| Margem Operacional (TTM) | -466.8%média 5A ≈-1558.0% | ≈-1558.0% | -474.4% | Primeira linha | |
| EBITDA Margin (Margem EBITDA) | -873.9%média 5A ≈-1558.0% | ≈-1558.0% | -474.4% | Primeira linha | |
| Pretax Margin (Margem de Impostos Pré-Tributação) | -765.9%média 5A ≈-434.8% | ≈-434.8% | -660.8% | Fraco | |
| Margem de Lucro Líquido (TTM) | -418.2%média 5A ≈-464.6% | ≈-464.6% | -442.9% | Primeira linha | |
| ROA (TTM) | -31.9%média 5A ≈22.9% | ≈22.9% | -34.8% | Primeira linha | |
| ROE (TTM) | -34.3%média 5A ≈13.4% | ≈13.4% | -76.5% | Primeira linha | |
| ROIC | -39.5% | · | -134.2% | Primeira linha |
Saúde financeira Dívida, liquidez, solvência — força do balanço patrimonial
| Métrica | Tendência de 5 anos | AGIO | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| Índice de liquidez corrente (MRQ) | 10.2média 5A ≈13.3 | ≈13.3 | 7.7 | Liquidez forte | |
| Quick Ratio (Índice de Liquidez Seca) | 1.1média 5A ≈1.8 | ≈1.8 | 4.3 | Baixa liquidez |
Crescimento Crescimento da receita, EPS e lucro líquido: YoY, CAGR 3 anos, CAGR 5 anos
| Métrica | Tendência de 5 anos | AGIO | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| Revenue YoY (Receita Ano a Ano) | 48.0%média 5A ≈57.5% | ≈57.5% | · | · | |
| Revenue CAGR 3Y (CAGR Receita 3A) | 56.0% | · | · | · | |
| EPS CAGR 3Y (CAGR de LPA 3A) | -24.0% | · | · | · | |
| Net Income CAGR 3Y (CAGR de Lucro Líquido 3A) | -25.1% | · | · | · |
Eficiência de Capital Giro de ativos, giro de estoques, giro de contas a receber
| Métrica | Tendência de 5 anos | AGIO | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| Asset Turnover (Giro do Ativo) | 0.0média 5A ≈0.0 | ≈0.0 | 0.3 | Fraco | |
| Inventory Turnover (Giro de Estoque) | 0.2média 5A ≈0.2 | ≈0.2 | · | · | |
| Revenue / Employee (Receita anual ÷ funcionários (número de funcionários reportado, yfinance). Derivado — não é um conceito SEC-XBRL armazenado.) | ≈$100.2K | · | · | · |
valor · ≈ média 5A · mediana do setor · veredicto relativo à mediana
Histórico de Lucros EPS real vs. estimativa, surpresa %, taxa de acerto, próxima data de resultados
Surpresa Média
5.5%
Próximo relatório
Out 28, 2026
| Período | Relatório | EPS Actual | EPS est. | Surpresa |
|---|---|---|---|---|
| 30 de Junho de 2026 | Jul 29, 2026 | $-1.69 | $-1.70 | 0.66% |
| 31 de Março de 2026 | $-1.69 | $-1.84 | 8.0% | |
| 31 de Dezembro de 2025 | $-1.86 | $-1.99 | 6.3% | |
| 30 de Setembro de 2025 | $-1.78 | $-1.94 | 8.1% | |
| 30 de Junho de 2025 | $-1.93 | $-1.84 | -4.7% | |
| 31 de Março de 2025 | $-1.55 | $-1.82 | 14.8% |
Fundamentos Completos Todas as métricas por ano — demonstração de resultados, balanço patrimonial, fluxo de caixa
Demonstração de Resultados
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $54M | $36M | $27M | $14M | $0 | $0 | $118M | $94M | $43M | $70M | $59M | $65M | |
| Cost of Revenue | $6M | $4M | $3M | $2M | $0 | $0 | $1M | $1M | $0 | $0 | · | · | |
| R&D Expense | $340M | $301M | $296M | $280M | $257M | $221M | $214M | $341M | $293M | $220M | $142M | $100M | |
| SG&A Expense | $180M | $157M | $120M | $122M | $121M | $115M | $102M | $114M | $71M | $51M | $36M | $19M | |
| Operating Expenses | $526M | $462M | $418M | $403M | $378M | $336M | $316M | $457M | $364M | $271M | $178M | $119M | |
| Operating Income | $-472M | $-426M | $-391M | $-389M | $-378M | $-336M | $-316M | $-362M | $-321M | $-201M | $-119M | $-54M | |
| Interest Income | · | · | · | $13M | $836.0K | $7M | $15M | $16M | $6M | $3M | $968.0K | $203.0K | |
| Other Non-op | $2M | $6M | $6M | $7M | $14M | $0 | $0 | · | · | · | · | · | |
| Pretax Income | $-414M | $718M | $-352M | $-232M | $-357M | $-329M | $-301M | $-346M | $-315M | $-198M | $-118M | $-54M | |
| Income Tax | $-1M | $44M | $0 | $0 | · | · | $0 | $0 | $0 | $0 | $0 | $-426.0K | |
| Net Income | $-413M | $674M | $-352M | $-232M | $1.60B | $-327M | $-411M | $-346M | $-315M | $-198M | $-118M | $-54M | |
| EPS (Basic) | $-7.12 | $11.86 | $-6.33 | $-4.23 | $26.55 | $-4.74 | $-6.86 | · | · | · | · | · | |
| EPS (Diluted) | $-7.12 | $11.64 | $-6.33 | $-4.23 | $26.55 | $-4.74 | $-6.86 | · | · | · | · | · | |
| Shares (Basic) | 57,972,004 | 56,807,415 | 55,651,487 | 54,789,435 | 60,447,346 | 68,997,879 | 59,994,539 | · | · | · | · | · | |
| Shares (Diluted) | 57,972,004 | 57,889,255 | 55,651,487 | 54,789,435 | 60,447,346 | 68,997,879 | 59,994,539 | · | · | · | · | · | |
| EBITDA | $-472M | $-426M | $-391M | $-389M | $-378M | $-316M | $-418M | $-362M | $-321M | $-201M | $-119M | $-54M |
Balanço Patrimonial
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $89M | $76M | $88M | $139M | $203M | $127M | $81M | $71M | $103M | $161M | $72M | $14M | |
| Short-term Investments | · | · | · | · | · | · | · | $515M | $321M | $381M | · | · | |
| Inventory | $33M | $28M | $19M | $8M | $0 | $15M | $7M | $869.0K | $0 | · | · | · | |
| Prepaid Expense | $44M | $40M | $35M | $39M | $40M | $16M | $24M | $17M | $18M | $10M | $9M | $5M | |
| Current Assets | $942M | $966M | $834M | $833M | $1.06B | $637M | $612M | $614M | $445M | $560M | $337M | $360M | |
| PP&E (Net) | $11M | $12M | $15M | $23M | $29M | $31M | $31M | $24M | $24M | $25M | $23M | $6M | |
| PP&E (Gross) | $71M | $68M | $68M | $73M | $74M | $72M | $64M | $50M | $44M | $39M | $31M | $12M | |
| Accum. Depreciation | $60M | $56M | $52M | $50M | $45M | $41M | $32M | $26M | $19M | $13M | $8M | $6M | |
| Other Non-current Assets | $4M | $5M | $4M | $4M | $3M | $0 | $0 | $238.0K | $891.0K | $2M | $611.0K | $590.0K | |
| Total Assets | $1.30B | $1.66B | $937M | $1.24B | $1.44B | $853M | $891M | $858M | $614M | $619M | $420M | $492M | |
| Accounts Payable | $18M | $17M | $10M | $19M | $17M | $18M | $22M | $18M | $23M | $17M | $15M | $11M | |
| Accrued Liabilities | $45M | $47M | $43M | $30M | $32M | $31M | $53M | $42M | $34M | $32M | $16M | $14M | |
| Current Liabilities | $82M | $81M | $68M | $63M | $60M | $94M | $93M | $94M | $95M | $88M | $53M | $61M | |
| Capital Leases | $22M | $40M | $57M | $72M | $86M | $97M | $106M | · | · | · | · | · | |
| Other Non-current Liabilities | $90.0K | $880.0K | $1M | $3M | $0 | · | · | · | · | · | · | · | |
| Total Liabilities | $104M | $122M | $126M | $138M | $146M | $453M | $250M | $171M | $239M | $261M | · | · | |
| Common Stock | · | · | · | · | $71.0K | $69.0K | $68.0K | $58.0K | $49.0K | $42.0K | $38.0K | $37.0K | |
| Retained Earnings | $-562M | $-149M | $-823M | $-471M | $-239M | $-1.84B | $-1.52B | $-1.10B | $-798M | $-483M | $-285M | $-167M | |
| Treasury Stock | $802M | $802M | $802M | $802M | $802M | $0 | · | · | · | · | · | · | |
| Stockholders' Equity | $1.19B | $1.54B | $811M | $1.10B | $1.29B | $400M | $641M | $688M | $376M | $359M | $345M | $424M | |
| Liabilities + Equity | $1.30B | $1.66B | $937M | $1.24B | $1.44B | $853M | $891M | $858M | $614M | $619M | $420M | $492M | |
| Shares Outstanding | 58,448,592 | 73,372,696,000 | 72,161,489 | 71,256,118 | 70,550,631 | 69,293,920 | 68,401,105 | 58,218,653 | 48,826,153 | 42,220,444 | 37,696,502 | 37,100,513 |
Fluxo de Caixa
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | $8M | $7M | $6M | · | · | · | |
| Stock-based Comp | $53M | $43M | $45M | $49M | $54M | $62M | $58M | $73M | $48M | $42M | $32M | $12M | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | $0 | $0 | $0 | |
| Other Non-cash | · | · | · | · | · | · | $-40M | · | · | · | · | · | |
| Operating Cash Flow | $-373M | $-390M | $-296M | $-309M | $-407M | $-291M | $-371M | $-304M | $-285M | $39M | $-77M | $-59M | |
| CapEx | $4M | $2M | $999.0K | $5M | $6M | $14M | $12M | $7M | $5M | $10M | $20M | $2M | |
| Investing Cash Flow | $377M | $363M | $240M | $243M | $1.25B | $76M | $91M | $-274M | $-58M | $-119M | $128M | · | |
| Stock Issued | · | · | · | · | $0 | $0 | $277M | $516M | $270M | $162M | $0 | $334M | |
| Net Stock Activity | · | · | · | · | $0 | $0 | $277M | $516M | $270M | $162M | · | $334M | |
| Financing Cash Flow | $9M | $14M | $5M | $2M | $-766M | $262M | $290M | $546M | $285M | $170M | $6M | · | |
| Net Change in Cash | $13M | $-12M | $-51M | $-64M | $76M | $47M | $10M | $-32M | $-58M | $89M | $58M | $-58M | |
| Taxes Paid | $628.0K | $43M | $2M | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $-377M | $-392M | $-297M | $-314M | $-413M | $-306M | $-383M | $-311M | $-290M | $29M | $-97M | $-62M |
Lucratividade
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -873.9% | -1166.5% | -1459.5% | -2732.1% | · | -155.6% | -361.6% | · | -745.8% | · | · | -82.8% | |
| Net Margin | -764.0% | 1845.9% | -1312.6% | -1627.8% | · | -161.1% | -349.0% | · | -731.6% | · | · | -81.9% | |
| Pretax Margin | -765.9% | 1967.2% | -1312.6% | -1627.8% | · | -161.2% | -349.0% | · | -731.6% | · | · | -82.5% | |
| EBITDA Margin | -873.9% | -1166.5% | -1459.5% | -2732.1% | · | -155.6% | -354.7% | · | -745.8% | · | · | -82.8% | |
| ROA | -27.9% | 51.8% | -32.4% | -17.3% | 140.1% | -37.5% | -47.0% | -47.0% | -51.0% | -38.2% | -25.8% | -15.4% | |
| ROE | -32.2% | 42.5% | -41.5% | -21.6% | 119.4% | -74.4% | -75.6% | -47.8% | -85.7% | -56.4% | -30.6% | -19.2% | |
| ROIC | -39.5% | -25.9% | · | · | · | · | -66.6% | -52.7% | -85.4% | · | · | -12.7% |
Liquidez e Solvência
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 11.5 | 11.9 | 12.3 | 13.3 | 17.8 | 6.7 | 6.6 | 6.6 | 4.7 | 6.3 | 6.4 | 5.9 | |
| Quick Ratio | 1.1 | 0.9 | 1.3 | 2.2 | 3.4 | 1.4 | 0.9 | 6.3 | 4.5 | 1.8 | 1.4 | 0.2 |
Eficiência
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | 0.0 | 0.0 | · | 0.2 | 0.1 | · | 0.1 | · | · | 0.2 | |
| Inventory Turnover | 0.2 | 0.2 | 0.2 | 0.4 | · | 0.3 | 0.3 | 3.2 | · | · | · | · |
Por Ação
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $20.41 | $26.96 | $14.50 | $20.00 | $23.78 | $5.77 | $9.36 | $11.81 | $7.69 | $8.49 | $9.16 | $11.44 | |
| Revenue / Share | $0.93 | $0.63 | $0.48 | $0.26 | · | · | · | · | · | · | · | · | |
| Cash Flow / Share | $-6.43 | $-6.73 | $-5.32 | $-5.65 | $-6.74 | · | · | · | · | · | · | · | |
| Cash / Share | $1.52 | $1.33 | $1.58 | $2.53 | $3.74 | $1.84 | $1.18 | $1.21 | $2.10 | $3.81 | $1.90 | $0.38 | |
| EPS (TTM) | $-7.12 | $11.64 | $-6.33 | $-4.23 | $26.55 | $-4.74 | $-6.86 | · | · | · | · | $-1.59 |
Taxas de Crescimento
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 48.0% | 36.1% | 88.4% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 56.0% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | · | -24.0% | · | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | · | -25.1% | · | · | · | · | · | · | · | · | · | · |
Avaliação (TTM)
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $54M | $36M | $27M | $14M | $0 | $0 | $118M | $94M | $43M | $70M | $59M | $65M | |
| Net Income TTM | $-413M | $674M | $-352M | $-232M | $1.60B | $-327M | $-411M | $-346M | $-315M | $-198M | $-118M | $-54M | |
| Market Cap | $1.59B | $1.88B | $1.25B | $1.55B | $1.79B | $3.00B | $3.27B | $2.68B | $2.79B | $1.76B | $2.45B | $4.16B | |
| P/E | -3.8 | 2.8 | -3.5 | -6.6 | 1.2 | -9.1 | -7.0 | · | · | · | · | -70.5 | |
| P/S | 29.4 | 51.5 | 46.4 | 108.5 | · | · | 27.7 | 28.4 | 64.9 | 25.2 | 41.4 | 63.6 | |
| P/B | 1.3 | 1.2 | 1.5 | 1.4 | 1.4 | 7.5 | 5.1 | 3.9 | 7.4 | 4.9 | 7.1 | 9.8 | |
| P / Tangible Book | 1.3 | 1.2 | 1.5 | 1.4 | 1.4 | 7.5 | · | · | · | · | · | · | |
| P / Cash Flow | -4.3 | -4.8 | -4.2 | -5.0 | -4.4 | -10.3 | -8.8 | -8.8 | -9.8 | 45.7 | -31.8 | -70.0 | |
| P / FCF | -4.2 | -4.8 | -4.2 | -4.9 | -4.3 | -9.8 | -8.5 | -8.6 | -9.6 | 61.5 | -25.2 | -67.5 | |
| Earnings Yield | -26.2% | 35.4% | -28.4% | -15.1% | 80.8% | -10.9% | -14.4% | · | · | · | · | -1.4% |
Demonstração de Resultados
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $45M | $21M | $20M | $13M | $12M | $9M | $11M | $9M | $9M | $8M | $7M | $7M | $7M | $6M | $4M | $4M | |
| Cost of Revenue | $3M | $1M | $2M | $2M | $2M | $1M | $1M | $783.0K | $1M | $627.0K | $586.0K | $633.0K | $1M | $554.0K | $413.0K | $517.0K | |
| R&D Expense | $101M | $81M | $88M | $87M | $92M | $73M | $83M | $72M | $77M | $69M | $77M | $82M | $69M | $67M | $70M | $65M | |
| SG&A Expense | $52M | $48M | $52M | $41M | $46M | $42M | $52M | $39M | $36M | $31M | $35M | $26M | $30M | $28M | $33M | $29M | |
| Operating Expenses | $155M | $131M | $142M | $130M | $140M | $115M | $136M | $112M | $114M | $100M | $113M | $108M | $100M | $96M | $103M | $95M | |
| Operating Income | $-111M | $-110M | $-122M | $-117M | $-127M | $-107M | $-125M | $-103M | $-106M | $-92M | $-106M | $-101M | $-94M | $-91M | $-99M | $-91M | |
| Other Non-op | $119.0K | $119.0K | $113.0K | $67.0K | $523.0K | $1M | $2M | $2M | $2M | $2M | $2M | $1M | $2M | $2M | $1M | $1M | |
| Pretax Income | · | · | $-109M | $-103M | · | · | $-105M | $1.00B | · | · | $-96M | $-91M | · | · | · | · | |
| Income Tax | · | · | $-1M | $0 | · | · | $-9M | $53M | · | · | $0 | $0 | · | · | $0 | $0 | |
| Net Income | $-101M | $-99M | $-108M | $-103M | $-112M | $-89M | $-97M | $948M | $-96M | $-82M | $-96M | $-91M | $-84M | $-81M | $37M | $-82M | |
| EPS (Basic) | $-1.69 | $-1.69 | $-1.86 | $-1.78 | $-1.93 | $-1.55 | $-1.65 | $16.65 | $-1.69 | $-1.45 | $-1.71 | $-1.64 | $-1.51 | $-1.47 | $0.68 | $-1.49 | |
| EPS (Diluted) | $-1.69 | $-1.69 | $-1.86 | $-1.78 | $-1.93 | $-1.55 | $-1.44 | $16.22 | $-1.69 | $-1.45 | $-1.71 | $-1.64 | $-1.51 | $-1.47 | $0.68 | $-1.49 | |
| Shares (Basic) | 59,488,871 | 58,782,241 | · | 58,139,277 | 57,932,576 | 57,459,195 | · | 56,939,403 | 56,802,546 | 56,383,475 | · | 55,803,663 | 55,604,330 | 55,265,390 | · | 54,844,579 | |
| Shares (Diluted) | 59,488,871 | 58,782,241 | · | 58,139,277 | 57,932,576 | 57,459,195 | · | 58,432,796 | 56,802,546 | 56,383,475 | · | 55,803,663 | 55,604,330 | 55,265,390 | · | 54,844,579 | |
| EBITDA | $-111M | $-110M | · | $-117M | $-127M | $-107M | · | $-103M | $-106M | $-92M | · | $-101M | $-94M | $-91M | · | $-91M |
Balanço Patrimonial
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $100M | $114M | $89M | $93M | $81M | $79M | $76M | $254M | $85M | $119M | · | $64M | $85M | $104M | · | $122M | |
| Inventory | $36M | $35M | $33M | $32M | $31M | $30M | $28M | $26M | $24M | $23M | · | $17M | $16M | $11M | · | $5M | |
| Prepaid Expense | $46M | $47M | $44M | $43M | $45M | $42M | $40M | $40M | $35M | $39M | · | $38M | $37M | $39M | · | $46M | |
| Current Assets | $718M | $835M | $942M | $1.03B | $1.02B | $969M | $966M | $1.07B | $632M | $664M | · | $704M | $757M | $792M | · | $785M | |
| PP&E (Net) | $10M | $11M | $11M | $11M | $11M | $11M | $12M | $12M | $13M | $14M | · | $17M | $20M | $21M | · | $25M | |
| PP&E (Gross) | · | · | $71M | · | · | · | $68M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $60M | · | · | · | $56M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Assets | $10M | $4M | $4M | $4M | $4M | $5M | $5M | $4M | $4M | $4M | · | $4M | $4M | $4M | · | $4M | |
| Total Assets | $1.11B | $1.18B | $1.30B | $1.39B | $1.47B | $1.56B | $1.66B | $1.79B | $773M | $850M | · | $1.01B | $1.09B | $1.15B | · | $1.18B | |
| Accounts Payable | $16M | $14M | $18M | $20M | $18M | $14M | $17M | $17M | $10M | $11M | · | $13M | $12M | $9M | · | $10M | |
| Accrued Liabilities | $35M | $26M | $45M | $37M | $35M | $21M | $47M | $33M | $37M | $25M | · | $30M | $29M | $22M | · | $30M | |
| Current Liabilities | $70M | $59M | $82M | $75M | $70M | $52M | $81M | $119M | $63M | $52M | · | $58M | $55M | $45M | · | $54M | |
| Capital Leases | $12M | $17M | $22M | $27M | $31M | $36M | $40M | $45M | $49M | $53M | · | $61M | $65M | $68M | · | $75M | |
| Other Non-current Liabilities | $240.0K | $90.0K | $90.0K | $90.0K | $101.0K | $880.0K | $880.0K | $1M | $1M | $1M | · | $1M | $1M | $1M | · | $1M | |
| Total Liabilities | $82M | $76M | $104M | $101M | $102M | $89M | $122M | $165M | $113M | $106M | · | $120M | $121M | $115M | · | $130M | |
| Retained Earnings | $-762M | $-661M | $-562M | $-454M | $-350M | $-238M | $-149M | $-52M | $-1.00B | $-904M | · | $-727M | $-635M | $-552M | · | $-507M | |
| Treasury Stock | $802M | $802M | $802M | $802M | $802M | $802M | $802M | $802M | $802M | $802M | · | $802M | $802M | $802M | · | $802M | |
| Stockholders' Equity | $1.03B | $1.11B | $1.19B | $1.28B | $1.37B | $1.47B | $1.54B | $1.63B | $661M | $744M | $811M | $887M | $964M | $1.04B | $1.10B | $1.05B | |
| Liabilities + Equity | $1.11B | $1.18B | $1.30B | $1.39B | $1.47B | $1.56B | $1.66B | $1.79B | $773M | $850M | · | $1.01B | $1.09B | $1.15B | · | $1.18B | |
| Shares Outstanding | 59,604,830 | 59,341,338 | 58,448,592 | 58,279,876 | 58,038,545 | 57,886,781 | 57,156,285 | 57,021,543 | 56,875,079 | 56,751,511 | 72,161,489 | 55,883,973 | 55,734,775 | 55,541,367 | 71,256,118 | 54,894,031 |
Fluxo de Caixa
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $16M | $16M | $14M | $12M | $15M | $11M | $11M | $11M | $12M | $9M | $14M | $9M | $12M | $10M | $11M | $11M | |
| Operating Cash Flow | $-57M | $-119M | $-96M | $-88M | $-77M | $-111M | $-133M | $-84M | $-73M | $-100M | $-72M | $-62M | $-67M | $-95M | $-66M | $-71M | |
| CapEx | $1M | $769.0K | $1M | $2M | $875.0K | $766.0K | $967.0K | $419.0K | $158.0K | $141.0K | $234.0K | $369.0K | $-3.0K | $399.0K | $113.0K | $38.0K | |
| Investing Cash Flow | $40M | $141M | $90M | $96M | $79M | $113M | $-49M | $251M | $37M | $125M | $96M | $39M | $47M | $58M | $83M | $104M | |
| Stock Repurchased | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | |
| Financing Cash Flow | $3M | $2M | $3M | $4M | $65.0K | $2M | $5M | $3M | $1M | $6M | $847.0K | $2M | $237.0K | $2M | $22.0K | $1M | |
| Net Change in Cash | $-14M | $24M | $-4M | $12M | $2M | $3M | $-177M | $169M | $-34M | $31M | $24M | $-20M | $-19M | $-35M | $17M | $34M | |
| Taxes Paid | $70.0K | $4.0K | $-940.0K | $65.0K | $1M | $188.0K | $44M | $-34.0K | $-78.0K | $-525.0K | $-17.0K | $785.0K | $801.0K | $0 | · | $98.0K | |
| Free Cash Flow | · | $-120M | · | · | · | $-112M | · | · | · | $-100M | · | · | · | $-96M | · | · |
Lucratividade
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -247.1% | -530.3% | · | -907.4% | -1020.1% | -1222.0% | · | -1146.9% | -1228.3% | -1124.3% | · | -1363.7% | -1396.0% | -1615.5% | · | -2590.7% | |
| Net Margin | -225.1% | -477.7% | · | -803.0% | -899.4% | -1023.2% | · | 10574.7% | -1115.7% | -995.8% | · | -1234.3% | -1248.6% | -1444.4% | · | -2325.0% | |
| Pretax Margin | · | · | · | -803.0% | · | · | · | 11167.3% | · | · | · | · | · | · | · | · | |
| EBITDA Margin | -247.1% | -530.3% | · | -907.4% | -1020.1% | -1222.0% | · | -1146.9% | -1228.3% | -1124.3% | · | -1363.7% | -1396.0% | -1615.5% | · | -2590.7% | |
| ROA | -7.8% | -7.2% | · | -6.5% | -10.0% | -7.4% | · | 67.7% | -10.3% | -8.2% | · | -8.3% | -7.2% | -6.5% | · | -6.0% | |
| ROE | -8.4% | -7.7% | · | -7.1% | -11.0% | -8.1% | · | 75.4% | -11.8% | -9.2% | · | -9.4% | -8.0% | -7.2% | · | -6.7% | |
| ROIC | · | · | · | -9.1% | · | · | · | -6.0% | · | · | · | · | · | · | · | · |
Liquidez e Solvência
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.2 | 14.2 | · | 13.8 | 14.5 | 18.5 | · | 9.0 | 10.1 | 12.8 | · | 12.1 | 13.7 | 17.5 | · | 14.6 | |
| Quick Ratio | 1.4 | 1.9 | · | 1.2 | 1.1 | 1.5 | · | 2.1 | 1.3 | 2.3 | · | 1.1 | 1.5 | 2.3 | · | 2.3 |
Eficiência
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Inventory Turnover | 0.1 | 0.0 | · | 0.1 | 0.1 | 0.0 | · | 0.0 | 0.1 | 0.0 | · | 0.1 | 0.1 | 0.1 | · | 0.1 |
Por Ação
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $17.21 | $18.69 | · | $22.04 | $23.60 | $25.33 | · | $28.53 | $11.61 | $13.11 | · | $15.87 | $17.30 | $18.66 | · | $19.13 | |
| Revenue / Share | $0.75 | $0.35 | · | $0.22 | $0.21 | $0.15 | · | $0.15 | $0.15 | $0.15 | · | $0.13 | $0.12 | $0.10 | · | $0.06 | |
| Cash Flow / Share | · | $-2.02 | · | · | · | $-1.94 | · | · | · | $-1.77 | · | · | · | $-1.72 | · | · | |
| Cash / Share | $1.67 | $1.91 | · | $1.59 | $1.39 | $1.36 | · | $4.45 | $1.49 | $2.09 | · | $1.15 | $1.52 | $1.88 | · | $2.23 | |
| EPS (TTM) | $-7.02 | $-7.26 | · | $-6.70 | $11.30 | $11.54 | · | $11.37 | $-6.49 | $-6.31 | · | $-3.94 | $-3.79 | $-3.96 | · | $-2.34 |
Avaliação (TTM)
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $98M | $66M | · | $45M | $41M | $37M | · | $33M | $31M | $29M | · | $24M | $20M | $19M | · | $10M | |
| Net Income TTM | $-411M | $-423M | · | $-401M | $650M | $666M | · | $674M | $-365M | $-353M | · | $-220M | $-210M | $-218M | · | $-363M | |
| Market Cap | $2.21B | $2.01B | · | $2.34B | $1.93B | $1.70B | · | $2.53B | $2.45B | $1.66B | · | $1.38B | $1.58B | $1.28B | · | $1.55B | |
| P/E | -5.3 | -4.7 | · | -6.0 | 2.9 | 2.5 | · | 3.9 | -6.6 | -4.6 | · | -6.3 | -7.5 | -5.8 | · | -12.1 | |
| P/S | 22.5 | 30.4 | · | 52.2 | 47.2 | 45.8 | · | 77.1 | 78.3 | 56.4 | · | 57.6 | 78.3 | 67.1 | · | 156.3 | |
| P/B | 2.2 | 1.8 | · | 1.8 | 1.4 | 1.2 | · | 1.6 | 3.7 | 2.2 | · | 1.6 | 1.6 | 1.2 | · | 1.5 | |
| P / Tangible Book | 2.2 | 1.8 | · | 1.8 | 1.4 | 1.2 | · | 1.6 | 3.7 | 2.2 | · | 1.6 | 1.6 | 1.2 | · | 1.5 | |
| P / Cash Flow | · | -16.9 | · | · | · | -15.2 | · | · | · | -16.6 | · | · | · | -13.4 | · | · | |
| Earnings Yield | -18.9% | -21.5% | · | -16.7% | 34.0% | 39.4% | · | 25.6% | -15.0% | -21.6% | · | -15.9% | -13.4% | -17.2% | · | -8.3% |
Período mais recente à esquerda · valores nulos mostrados como ·
Demonstrações Financeiras Demonstração de resultados, balanço patrimonial, fluxo de caixa — anual, últimos 5 anos
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Receita | $54M | $36M | $27M | $14M | $0 |
| Margem Operacional % | -873.9% | -1166.5% | -1459.5% | -2732.1% | · |
| Lucro líquido | $-413M | $674M | $-352M | $-232M | $1.60B |
| EPS Diluído | $-7.12 | $11.64 | $-6.33 | $-4.23 | $26.55 |
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Índice de liquidez corrente | 11.5 | 11.9 | 12.3 | 13.3 | 17.8 |
| Índice de Liquidez Seca | 1.1 | 0.9 | 1.3 | 2.2 | 3.4 |
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Fluxo de caixa livre | $-377M | $-392M | $-297M | $-314M | $-413M |
Investidores institucionais (13F) 262 declarantes · $2.7B total · Em 30 de Setembro de 2026
Instituições que relatam a posse desta ação em seu Formulário 13F trimestral da SEC. Apenas posições compradas; um único declarante pode aparecer duas vezes para opções separadas. Grandes posições de compra/venda compensatórias geralmente refletem market-making ou inventário protegido, não convicção direcional.
Detentores
262
Valor detido
$2.7B
Novas posições
39
Posições encerradas
30
Atividade institucional — Q2 2026 vs trimestre anterior
| Novas posições | Posições encerradas | Aumentou | Diminuído | Variação líquida de ações |
|---|---|---|---|---|
| 39 (-2 vs trimestre anterior) | 30 (-2 vs trimestre anterior) | 96 (+16 vs trimestre anterior) | 69 (-19 vs trimestre anterior) | +8.4M |
Comparado a Q1 2026. Os registros do Formulário 13F da SEC devem ser feitos em até 45 dias após o final do trimestre, mais um pequeno período de tolerância para registrantes atrasados — trimestres ainda dentro desse período são ignorados em favor do par mais recente totalmente reportado.
| Instituição | Valor | Ações | % de 13F rastreado | Tipo |
|---|---|---|---|---|
| BlackRock, Inc. | $239.582.050 | 6.455.997 | 8,88% | Ações |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | $219.594.714 | 5.917.400 | 8,14% | Ações |
| VANGUARD GROUP INC | $152.278.288 | 5.594.353 | 5,64% | Ações |
| STATE STREET CORP | $131.144.972 | 3.533.633 | 4,86% | Ações |
| Lynx1 Capital Management LP | $126.505.652 | 3.408.937 | 4,69% | Ações |
| D. E. Shaw & Co., Inc. | $115.300.956 | 3.107.005 | 4,27% | Ações |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $107.552.091 | 2.898.197 | 3,98% | Ações |
| ARMISTICE CAPITAL, LLC | $104.279.100 | 2.810.000 | 3,86% | Opção de compra |
| VANGUARD CAPITAL MANAGEMENT LLC | $99.523.268 | 2.681.845 | 3,69% | Ações |
| ARMISTICE CAPITAL, LLC | $89.064.000 | 2.400.000 | 3,30% | Ações |
| Erste Asset Management GmbH | $81.972.396 | 2.154.900 | 3,04% | Ações |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $78.332.000 | 2.110.809 | 2,90% | Ações |
| GEODE CAPITAL MANAGEMENT, LLC | $58.433.490 | 1.574.268 | 2,17% | Ações |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $51.046.957 | 1.375.558 | 1,89% | Ações |
| ADAR1 Capital Management, LLC | $47.799.647 | 1.288.053 | 1,77% | Ações |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $47.502.433 | 1.280.044 | 1,76% | Ações |
| DIMENSIONAL FUND ADVISORS LP | $46.345.467 | 1.248.738 | 1,72% | Ações |
| GOLDMAN SACHS GROUP INC | $42.711.087 | 1.150.932 | 1,58% | Ações |
| UBS Group AG | $36.584.189 | 985.831 | 1,36% | Ações |
| MORGAN STANLEY | $35.746.487 | 963.256 | 1,32% | Ações |
| Nuveen, LLC | $32.417.811 | 873.560 | 1,20% | Ações |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $30.078.768 | 810.530 | 1,11% | Ações |
| Foresite Capital Management VI LLC | $29.131.350 | 785.000 | 1,08% | Ações |
| CITADEL ADVISORS LLC | $27.190.015 | 732.687 | 1,01% | Ações |
| AQR CAPITAL MANAGEMENT LLC | $25.395.858 | 684.340 | 0,94% | Ações |
| Parkman Healthcare Partners LLC | $24.828.297 | 669.046 | 0,92% | Ações |
| SCS Capital Management LLC | $22.742.864 | 612.850 | 0,84% | Ações |
| Qube Research & Technologies Ltd | $22.178.346 | 597.638 | 0,82% | Ações |
| NORTHERN TRUST CORP | $20.585.250 | 554.709 | 0,76% | Ações |
| Defilade Capital Management, L.P. | $20.293.529 | 546.848 | 0,75% | Ações |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $19.969.930 | 538.128 | 0,74% | Ações |
| TWO SIGMA INVESTMENTS, LP | $19.905.062 | 536.380 | 0,74% | Ações |
| Rock Springs Capital Management LP | $19.763.413 | 532.563 | 0,73% | Ações |
| Schonfeld Strategic Advisors LLC | $19.300.279 | 520.083 | 0,72% | Ações |
| BANK OF AMERICA CORP /DE/ | $18.847.034 | 507.869 | 0,70% | Ações |
| Point72 Asset Management, L.P. | $18.790.426 | 506.344 | 0,70% | Ações |
| JANE STREET GROUP, LLC | $18.280.312 | 492.598 | 0,68% | Ações |
| Legal & General Group Plc | $16.132.422 | 434.719 | 0,60% | Ações |
| VANGUARD FIDUCIARY TRUST CO | $14.690.661 | 395.868 | 0,54% | Ações |
| PANAGORA ASSET MANAGEMENT INC | $13.876.579 | 373.931 | 0,51% | Ações |
| KENNEDY CAPITAL MANAGEMENT LLC | $13.850.565 | 373.230 | 0,51% | Ações |
| JPMORGAN CHASE & CO | $13.783.528 | 359.756 | 0,51% | Ações |
| Connor, Clark & Lunn Investment Management Ltd. | $13.342.901 | 359.550 | 0,49% | Ações |
| Squarepoint Ops LLC | $11.917.431 | 321.138 | 0,44% | Ações |
| Ensign Peak Advisors, Inc | $11.045.049 | 297.630 | 0,41% | Ações |
| BNP PARIBAS FINANCIAL MARKETS | $9.996.803 | 269.383 | 0,37% | Ações |
| ALGERT GLOBAL LLC | $9.203.540 | 248.007 | 0,34% | Ações |
| JANE STREET GROUP, LLC | $7.974.939 | 214.900 | 0,30% | Opção de venda |
| Palo Alto Investors LP | $7.926.733 | 213.601 | 0,29% | Ações |
| Tetragon Partners GP Ltd | $7.629.037 | 205.579 | 0,28% | Ações |
Ativistas e proprietários de 5%+ 3 participações
Investidores que apresentaram o Schedule 13D da SEC — propriedade benéfica acima de 5% com a intenção de influenciar o emissor (participações ativistas, campanhas no conselho, M&A). Cada linha mostra o estado mais recente conhecido da posição desse declarante.
| Declarante | Declarado | Participação | Status | Propósito | Declaração |
|---|---|---|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY, CELGENE CORPORATION, CELGENE SWITZERLAND LLC, CELGENE EUROPEAN INVESTMENT COMPANY LLC, CELGENE ALPINE INVESTMENT CO., LLC | 5 de Abril de 2021 | · | Declaração inicial | · | SEC |
| CELGENE SWITZERLAND LLC, CELGENE EUROPEAN INVESTMENT COMPANY LLC, CELGENE ALPINE INVESTMENT CO., LLC, CELGENE CORPORATION ×3 declarações | 14 de Novembro de 2019 | · | Declaração inicial | Estrutura de capital | SEC |
| CELGENE EUROPEAN INVESTMENT COMPANY LLC, CELGENE ALPINE INVESTMENT CO., LLC, CELGENE CORPORATION ×3 declarações | 17 de Dezembro de 2014 | · | Declaração inicial | Estrutura de capital | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Executivos da empresa 38 insiders · 18 diretores · 20 conselheiros
| Investidor com informação privilegiada | Função | Última atividade | Ações detidas | Compras 12m | Vendas 12m | Líquido 12m |
|---|---|---|---|---|---|---|
| Brian Goff | Chief Executive Officer | 18 de Junho de 2026 A | 184.508 | 0 | 7 | $-1.691.387 |
| Cecilia Jones | Chief Financial Officer | 18 de Junho de 2026 A | 54.998 | 0 | 6 | $-334.266 |
| Jonathan Biller | Chief Financial Officer | 1 de Março de 2022 A | 22.953 | 0 | 0 | $0 |
| Andrew Hirsch | Chief Financial Officer | 22 de Abril de 2020 M | 24.272 | 0 | 0 | $0 |
| John Duncan Higgons | Chief Operating Officer | 4 de Janeiro de 2016 M | 120.834 | 0 | 0 | $0 |
| Sarah Gheuens | Chief Medical Officer | 4 de Agosto de 2026 S | 54.645 | 0 | 10 | $-1.625.034 |
| Krishnan Viswanadhan | Chief Strategy and Operations | 18 de Junho de 2026 A | 10.282 | 0 | 2 | $-184.967 |
| Tsveta Milanova | Chief Commercial Officer | 18 de Junho de 2026 A | 46.829 | 0 | 5 | $-353.311 |
| James William Burns | Chief Legal Officer | 18 de Junho de 2026 A | 49.306 | 0 | 6 | $-344.391 |
| Theodore James Washburn Jr. | Principal Accounting Officer | 3 de Março de 2026 S | 868 | 0 | 4 | $-216.633 |
| Richa Poddar | Chief Commercial Officer | 15 de Outubro de 2022 M | 8.508 | 0 | 0 | $0 |
| Bruce Car | Chief Scientific Officer | 1 de Março de 2022 A | 16.752 | 0 | 0 | $0 |
| Carman Alenson | Principal Accounting Officer | 21 de Junho de 2021 M | 0 | 0 | 0 | $0 |
| Christopher Bowden | Chief Medical Officer | 18 de Junho de 2021 M | 15.487 | 0 | 0 | $0 |
| Darrin Miles | Chief Commercial Officer | 14 de Maio de 2021 S | 7.209 | 0 | 0 | $0 |
| Scott Biller | Chief Scientific Officer | 11 de Junho de 2019 M | 33.729 | 0 | 0 | $0 |
| Steven L. Hoerter | Chief Commercial Officer | 4 de Março de 2019 M | 10.941 | 0 | 0 | $0 |
| Glenn Goddard | Senior Vice President, Finance | 16 de Fevereiro de 2016 A | 0 | 0 | 0 | $0 |
| Jay T. Backstrom | Conselheiro | 8 de Julho de 2026 M | 1.447 | 0 | 0 | $0 |
| Adams Catherine Owen | Conselheiro | 18 de Junho de 2026 A | 10.865 | 0 | 0 | $0 |
| Rahul D. Ballal | Conselheiro | 18 de Junho de 2026 A | 15.230 | 0 | 0 | $0 |
| David Scadden | Conselheiro | 18 de Junho de 2026 A | 20.419 | 0 | 2 | $-16.968 |
| Maykin Ho | Conselheiro | 18 de Junho de 2026 A | 19.848 | 0 | 0 | $0 |
| Cynthia Smith | Conselheiro | 18 de Junho de 2026 A | 15.230 | 0 | 0 | $0 |
| Jacqualyn A Fouse | Conselheiro | 18 de Junho de 2026 A | 154.156 | 0 | 0 | $0 |
| Kaye I Foster-Cheek | Conselheiro | 18 de Junho de 2026 A | 10.284 | 0 | 0 | $0 |
| Jeffrey D Capello | Conselheiro | 18 de Junho de 2026 A | 10.865 | 0 | 0 | $0 |
| David P Schenkein | Conselheiro | 20 de Junho de 2024 A | 126.242 | 0 | 0 | $0 |
| Paul J Clancy | Conselheiro | 21 de Junho de 2022 A | 6.549 | 0 | 0 | $0 |
| John Maraganore | Conselheiro | 21 de Junho de 2022 A | 30.028 | 0 | 0 | $0 |
| Ian T Clark | Conselheiro | 20 de Maio de 2022 M | 6.549 | 0 | 0 | $0 |
| Lewis Clayton Cantley Jr. | Conselheiro | 7 de Dezembro de 2017 S | 79.515 | 0 | 0 | $0 |
| Robert Nelsen | Conselheiro | 6 de Março de 2017 S | 0 | 0 | 0 | $0 |
| Douglas G. Cole | Conselheiro | 10 de Agosto de 2016 J | 2.778 | 0 | 0 | $0 |
| Marc Tessier-Lavigne | Conselheiro | 21 de Junho de 2016 A | 101.009 | 0 | 0 | $0 |
| Perry A Karsen | Conselheiro | 23 de Junho de 2015 A | · | 0 | 0 | $0 |
| Kevin P Starr | Conselheiro | 19 de Fevereiro de 2015 J | 184.386 | 0 | 0 | $0 |
| Celgene European Investment Co LLC | Detentor de 10% | 16 de Dezembro de 2014 P | 1.231.778 | 0 | 0 | $0 |
Executivos de declarações SEC Formulário 3/4/5; líquido = apenas P/V de mercado aberto
Participação em ETFs Detido por 43 ETFs
O peso reflete apenas participações diretas em ações (N-PORT); fundos alavancados ou baseados em derivativos podem deter exposição adicional a swaps não mostrada.
| Fundo | Peso | Unidades | Em | Fonte |
|---|---|---|---|---|
| BBP · ETFis Series Trust I | 1,40% | 46.067 NS | 31 de Julho de 2026 | N-PORT |
| HAPS · Harbor ETF Trust | 0,82% | 46.575 NS | 31 de Julho de 2026 | N-PORT |
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,51% | 3.546 SH | 1 de Outubro de 2026 | Diário |
| LABU · Direxion Shares ETF Trust | 0,41% | 67.945 NS | 31 de Julho de 2026 | N-PORT |
| FYC · First Trust Exchange-Traded AlphaDE… | 0,32% | 139.210 NS | 31 de Julho de 2026 | N-PORT |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,22% | 17.481 SH | 1 de Outubro de 2026 | Diário |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,15% | 121.574 SH | 30 de Setembro de 2026 | Diário |
| IBB · iShares Trust | 0,14% | 425.302 SH | 11 de Setembro de 2026 | Diário |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,13% | 48.730 SH | 19 de Agosto de 2026 | Diário |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,13% | 4.219 SH | 1 de Outubro de 2026 | Diário |
| PWS · Pacer Funds Trust | 0,12% | 928 NS | 31 de Julho de 2026 | N-PORT |
| FYX · First Trust Exchange-Traded AlphaDE… | 0,10% | 47.013 NS | 31 de Julho de 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,07% | 340.226 SH | 19 de Agosto de 2026 | Diário |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,07% | 12.610 NS | 31 de Julho de 2026 | N-PORT |
| IWM · iShares Trust | 0,07% | 1.511.496 SH | 11 de Setembro de 2026 | Diário |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,07% | 15.124 NS | 31 de Julho de 2026 | N-PORT |
| ESML · iShares Trust | 0,06% | 50.007 SH | 11 de Setembro de 2026 | Diário |
| VBK · VANGUARD INDEX FUNDS | 0,06% | 788.655 SH | 19 de Agosto de 2026 | Diário |
| RSSL · Global X Funds | 0,06% | 28.271 NS | 31 de Julho de 2026 | N-PORT |
| DFAS · Dimensional ETF Trust | 0,04% | 192.387 NS | 31 de Julho de 2026 | N-PORT |
| ISCG · iShares Trust | 0,04% | 10.228 SH | 11 de Setembro de 2026 | Diário |
| DXUV · Dimensional ETF Trust | 0,03% | 5.807 NS | 31 de Julho de 2026 | N-PORT |
| VB · VANGUARD INDEX FUNDS | 0,03% | 1.364.364 SH | 19 de Agosto de 2026 | Diário |
| VHT · VANGUARD WORLD FUND | 0,03% | 167.169 SH | 19 de Agosto de 2026 | Diário |
| FHLC · FIDELITY COVINGTON TRUST | 0,02% | 26.897 NS | 31 de Julho de 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,02% | 683.802 SH | 19 de Agosto de 2026 | Diário |
| WSML · iShares Trust | 0,02% | 3.364 SH | 11 de Setembro de 2026 | Diário |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,01% | 3.639 SH | 19 de Agosto de 2026 | Diário |
| DFAC · Dimensional ETF Trust | 0,01% | 148.210 NS | 31 de Julho de 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,01% | 9.209 NS | 31 de Julho de 2026 | N-PORT |
| IWO · iShares Trust | 0,01% | 31.737 SH | 11 de Setembro de 2026 | Diário |
| TILT · FlexShares Trust | 0,01% | 4.553 NS | 31 de Julho de 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0,00% | 17.627 NS | 31 de Julho de 2026 | N-PORT |
| IWV · iShares Trust | 0,00% | 16.716 SH | 11 de Setembro de 2026 | Diário |
| ITOT · iShares Trust | 0,00% | 76.792 SH | 11 de Setembro de 2026 | Diário |
| DFUS · Dimensional ETF Trust | 0,00% | 17.217 NS | 31 de Julho de 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 1.890.189 SH | 19 de Agosto de 2026 | Diário |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,00% | 46.943 SH | 19 de Agosto de 2026 | Diário |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 4.834 SH | 19 de Agosto de 2026 | Diário |
| ESGV · VANGUARD WORLD FUND | 0,00% | 13.097 SH | 19 de Agosto de 2026 | Diário |
| IWN · iShares Trust | · | 521.555 SH | 11 de Setembro de 2026 | Diário |
| ISCB · iShares Trust | · | 2.551 SH | 11 de Setembro de 2026 | Diário |
| ISCV · iShares Trust | · | 5.020 SH | 11 de Setembro de 2026 | Diário |
AGIO Consenso dos analistas Opiniões de analistas otimistas e pessimistas, preço-alvo de 12 meses, potencial de alta
classificação · 16 analistas
COMPRA
Alvo mediano
$44.50
+39,9%
5 31,2%
Compra forte
7 43,8%
Compra
4 25,0%
Manter
0 0,0%
Venda
0 0,0%
Venda forte
Preço-alvo de 12 meses
8 analistas · 2026-09-27Alvo médio $46.25 +45,4%
← Abaixo de todos os alvos
Preço atual $31.80
Mín$32.00
Média$46.25
Máx$73.00
Comparação de pares (subindústria GICS) Métricas chave vs pares do setor
Base do ano fiscal, preços no fechamento do último ano fiscal de cada empresa.
| Ticker | Capitalização de Mercado | P/E | Receita YoY | Margem Líquida | ROE | Margem Bruta |
|---|---|---|---|---|---|---|
| AGIO | $1.59B | -3.8 | 48.0% | -764.0% | -32.2% | · |
| MLYS | $2.96B | -15.8 | · | · | -32.2% | · |
| BCRX | $1.66B | 6.4 | 94.1% | 30.2% | -97.6% | · |
| ZBIO | $1.98B | -4.3 | 100.0% | -3777.4% | -156.8% | · |
| VCEL | $1.82B | 112.5 | 16.4% | 6.0% | 5.0% | 74.4% |
| BHVN | $1.50B | -1.6 | · | · | -310.8% | · |
| VIR | $841M | -1.9 | -7.6% | -638.9% | -51.1% | · |
| PVLA | $1.30B | -28.2 | 65.3% | -1610.6% | -110.1% | · |
| ABSI | $529M | -4.2 | -38.2% | -4113.7% | -63.5% | · |
| SRPT | $2.26B | -3.0 | 15.6% | -32.5% | -57.1% | · |
| GENB | · | · | · | · | · | · |
Últimas notícias Notícias recentes mencionando esta empresa
Minhas Métricas Sua lista pessoal — linhas selecionadas de Fundamentos Completos
Escolha as métricas que importam para si — clique no + ao lado de qualquer linha em Fundamentos Completos acima.
Sua seleção é salva e acompanha você em todos os tickers.
Fonte: SEC 10-Q arquivado Jul 30, 2026